ArticleThe Journal of physiology2013
Dampened dopamine-mediated neuromodulation in prefrontal cortex of fragile X mice.
Article in The Journal of physiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Altered olfactory responses in Fmr1 KO mice.Scientific reports · 2025Article
- The inhibition of NCS-1 binding to Ric8a rescues fragile X syndrome mice model phenotypes.Frontiers in neuroscience · 2022Article
- The Lack of Dopamine Transporter Is Associated With Conditional Associative Learning Impairments and Striatal Proteomic Changes.Frontiers in psychiatry · 2022Article
- Sex Differences in Dopamine Receptor Signaling inBrain sciences · 2021Article
- Dopaminergic Dysregulation in Syndromic Autism Spectrum Disorders: Insights From Genetic Mouse Models.Frontiers in neural circuits · 2021Review
- Reduced axonal caliber and structural changes in a rat model of Fragile X syndrome with a deletion of a K-Homology domain of Fmr1.Translational psychiatry · 2020Article
- Altered dopaminergic pathways and therapeutic effects of intranasal dopamine in two distinct mouse models of autism.Molecular brain · 2020Article
- Cortical Excitation:Inhibition Imbalance Causes Abnormal Brain Network Dynamics as Observed in Neurodevelopmental Disorders.Cerebral cortex (New York, N.Y. : 1991) · 2020Article
- The Gut-Immune-Brain Axis in Autism Spectrum Disorders; A Focus on Amino Acids.Frontiers in endocrinology · 2019Review
- Of Men and Mice: Modeling the Fragile X Syndrome.Frontiers in molecular neuroscience · 2018Article
- Effects of a social stimulus on gene expression in a mouse model of fragile X syndrome.Molecular autism · 2017Article
- Functional magnetic resonance imaging in awake transgenic fragile X rats: evidence of dysregulation in reward processing in the mesolimbic/habenular neural circuit.Translational psychiatry · 2016Article
- Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes.Frontiers in cellular neuroscience · 2015Review
- Differential effects of dopamine-directed treatments on cognition.Neuropsychiatric disease and treatment · 2015Review
- Increasing our understanding of human cognition through the study of Fragile X Syndrome.Developmental neurobiology · 2014Review
- Hyperactivity, perseveration and increased responding during attentional rule acquisition in the Fragile X mouse model.Frontiers in behavioral neuroscience · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Fragile X syndrome (FXS) is the most common form of inheritable mental retardation caused by transcriptional silencing of the Fmr1 gene resulting in the absence of fragile X mental retardation protein (FMRP). The role of this protein in neurons is complex and its absence gives rise to diverse alterations in neuronal function leading to neurological disorders including mental retardation, hyperactivity, cognitive impairment, obsessive-compulsive behaviour, seizure activity and autism. FMRP regulates mRNA translation at dendritic spines where synapses are formed, and thus the lack of FMRP can lead to disruptions in synaptic transmission and plasticity. Many of these neurological deficits in FXS probably involve the prefrontal cortex, and in this study, we have focused on modulatory actions of dopamine in the medial prefrontal cortex. Our data indicate that dopamine produces a long-lasting enhancement of evoked inhibitory postsynaptic currents (IPSCs) mediated by D1-type receptors seen in wild-type mice; however, such enhancement is absent in the Fmr1 knock-out (Fmr1 KO) mice. The facilitation of IPSCs produced by direct cAMP stimulation was unaffected in Fmr1 KO, but D1 receptor levels were reduced in these animals. Our results show significant disruption of dopaminergic modulation of synaptic transmission in the Fmr1 KO mice and this alteration in inhibitory activity may provide insight into potential targets for the rescue of deficits associated with FXS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.